Sign in
4

Changes in Ownership

Spyre Therapeutics, Inc. Filed Acc 0001140361-17-045129

Chief Financial Officer and VP bought 25,959 shares at an average $4.48 ($116,223)

From the SEC's structured data for this filing

Trades in this filing

York Charles N II · Chief Financial Officer and VP

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2016-08-15 Purchase : show line 1 in the form +2,000 $3.99 $7,974 10,828 D
2017-02-15 Purchase : show line 2 in the form +2,000 $4.28 $8,568 12,828 D
2017-08-15 Purchase : show line 3 in the form +1,959 $2.52 $4,929 14,787 D
2017-12-01 Purchase : show line 4 in the form +6,500 $4.59 $29,855 21,287 D
2017-12-04 Purchase : show line 5 in the form +3,259 $4.97 $16,197 24,546 D
2017-12-05 Purchase : show line 6 in the form +10,241 $4.76 $48,700 34,787 D
Open-market purchases · 25,959 sh · avg $4.48 · $116,223
Loading xslF345X03/doc1.xml…